Pharma major Dr Reddy's has signed a pact with Israeli-American drug firm Teva Pharmaceutical to buy a portfolio of eight abbreviated new drug applications (ANDAs) in the US for $350 million (around â‚¹2,300 crore). The combined sales of branded versions of these applications in the US, which include drugs pending approval and generic products, is $3.5 billion, it added. 